Fortis Healthcare Limited has informed the Exchange about Transcript
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare reported a strong Q1 FY26 with consolidated revenue of INR 2,167 crores, up 16.6% year-on-year, and operating EBITDA of INR 491 crores, up 43.2%, with margins expanding to 22.6% from 18.4%. Hospital business revenue grew 18.6% to INR 1,838 crores with EBITDA margins improving to 22.1%, while diagnostics revenue grew 6.3% with margins jumping to 23% from 16.1%. The company announced two key expansions: acquisition of Shrimann Superspecialty Hospital in Jalandhar (228 beds) and an O&M services agreement with Gleneagles India to manage about 700 beds for a 3% net revenue fee, taking total operational footprint to 33 facilities with over 5,700 beds. Management maintained its full-year guidance of 200 basis points margin improvement for hospitals and 22-23% margins for diagnostics, with plans to add about 900 beds this fiscal and bring back the legacy SRL brand alongside Agilus.
Strong quarterly performance, margin expansion, and visible capacity additions (~900 beds) along with the Gleneagles O&M contract should support earnings growth in FY26 and beyond. Higher debt from acquisitions (net debt/EBITDA at 0.92x vs 0.22x) is a watch point, but management's reiterated margin guidance and ARPOB growth of 10.2% signal continued operational momentum for shareholders.